Successful treatment of secondary poor graft function post allogeneic hematopoietic stem cell transplantation with eltrombopag

Table 1 Clinical Characteristics of the 12 sPGF patients

No.	Age	Sex	Underlying disease	Cytopenia	Failed previous treatments (duration)	Eltrom duration, weeks	Total dose of eltrom, mg	Time to CR, days	Best response	Last follow-up
1	21	M	ALL	N, PLT	G-CSF, EPO, TPO, IL-11 PLT transfusion-dependent for 12 months, MSC infusion for 4 times	13	6475	43	CR	Alive
2	25	F	ALL	N, HB, PLT	G-CSF, EPO, TPO, PLT transfusion-dependent for 2 months	2	700	10	CR	Alive
3	35	F	ALL	N, HB, PLT	G-CSF, EPO, TPO, RBC and PLT transfusion-dependent for 2 months	2	700	NA	PR	Dead
4	22	M	ALL	N, HB, PLT	G-CSF, PLT transfusion-dependent for 1 month	8	4200	NA	NR	Dead
5	52	M	AML	N, PLT	G-CSF, IL-11, PLT transfusion-dependent for 1 month	4	700	36	CR	Alive
6	27	F	AML	N, HB, PLT	G-CSF, EPO, TPO, RBC and PLT transfusion-dependent for 3 months	7	1725	NA	PR	Dead
7	53	M	AML	N, PLT	G-CSF, EPO, TPO, PLT transfusion-dependent for 1 month	6	2175	25	CR	Alive
8	42	M	MPAL	N, HB, PLT	G-CSF, EPO, TPO, RBC and PLT transfusion-dependent for 3 months; DAC for 1 course	4	1400	NA	NR	Alive
9	42	F	SAA	N, HB, PLT	G-CSF, PLT transfusion-dependent for 1 month; DAC for 1 course	8	4200	30	CR	Alive
10	29	F	SAA	N, PLT	G-CSF, TPO-dependent for 1 month	23	10,500	28	CR	Alive
11	33	M	SAA	N, PLT	G-CSF, EPO, TPO, PLT transfusion-dependent for 2 months, MSC infusion for 3 times	8	4025	49	CR	Alive
12	47	M	MF	N, PLT	G-CSF, PLT transfusion-dependent for 1 month	8	2800	20	CR	Alive

M male, F female, N neutrophil, HB hemoglobin, PLT platelet, sPGF secondary poor graft function, AML acute myeloid leukemia, ALL acute lymphocytic leukemia, MPAL mixed phenotype acute leukemia, SAA severe aplasia anemia, MF myelofibrosis, CR complete response, PR partial response, NR no response, G-CSF granulocyte colony-stimulating factor, EPO erythropoietin, TPO thrombopoietin, MSC mesenchymal stem cell, DAC decitabine, NA not available

ISSN: 1756-8722